Abstract
Herein, a versatile fluorescent bioanalysis platform for sensitive and specific screening of target miRNA (miR-129-2-3p) was innovatively designed by applying target-induced rolling circle amplification (RCA) for efficient signal amplification. Specifically, miR-129-2-3p was used as a ligation template to facilitate its ligation with padlock probes, followed by an RCA reaction in the presence of phi29 DNA polymerase. The dsDNA fragments and products were stained by SYBR Green I and then detected by fluorescence spectrophotometry. As a result, miR-129-2-3p concentrations as low as 50 nM could be detected. Furthermore, the expression of miR-129-2-3p in breast cancer patients was about twice that in healthy people. Therefore, the results indicated that the RCA-based biosensor system could be a valuable platform for miRNA detection in clinical diagnosis and biomedical study.
Keywords: RCA, Fluorescent detection, Biosensor, miR-129-2-3p
Introduction
MicroRNAs (miRNAs) are a group of conserved, endogenous non-coding and short RNA (18–25 nucleotides) that regulate gene expression and play essential roles in cells, including proliferation, migration, differentiation, apoptosis and death (Xu et al., 2019; Gregory et al., 2004; Bartel, 2004; Sawyers, 2008; Ambros, 2001; Rossi, 2009). MicroRNAs negatively regulate gene expression via eliciting mRNA degradation or suppressing protein translation by targeting the 3′ or 5′ untranslated region (UTR) of the target gene (Luan et al., 2016; Shazadi et al., 2014, Bartel Wang et al., 2021). Past studies have found that miRNAs, as post-transcriptional regulators of gene expression, are closely associated with a variety of diseases, including cancer (Jiang et al., 2005; Luby & Zheng, 2017; Volinia et al., 2006), and are related to cancer initiation, progression and response to treatments (Brito et al., 2014; Schetter et al., 2008; Asaga et al., 2011). Accordingly, miRNAs extracted from serum or tumor tissue have been regarded as biomarkers for cancer diagnosis (Li et al., 2014; Cao et al., 2011; Krazinski et al., 2019).
MiR-129-2-3p is a member of the miR-129 family and is abnormally expressed in some tumors (Xiao et al., 2015; Kang et al., 2013; Lu et al., 2013; Tian et al., 2015; Yang et al., 2015; Tang et al., 2016), which is thought to have an inhibitory effect on various types of tumors (Gao et al., 2016).
MiR-129-2-3p plays a pivotal role in gastric cancer by restraining its migration and proliferation in vitro and slowing down gastric cancer growth in vivo via the inhibition of WWP1 (Ma et al., 2019; Yu et al., 2013a; Yu et al., 2013b). Moreover, some researchers also found that the expression of sex-determining region Y-box 4 (SOX4) was negatively correlated with the expression of miR-129-2-3p and miR-129-5p in gastric cancer (Yu et al., 2013a; Yu et al., 2013b). Overexpression of miR-129-2-3p significantly inhibits the proliferation and induces apoptosis of breast cancer cells (Tang et al., 2016). The expression levels of miR-129-2-3p in Ewing sarcoma tumor tissue samples are significantly lower than those in corresponding adjacent normal tissue samples (Tanoglu et al., 2021). The aberrant expression of the miR-129-2-3p is also detected in lung adenocarcinoma (Zhang et al., 2021). In human intrahepatic cholangiocarcinoma tissues and cell lines, the expression is notably decreased and the low expression of miR-129-2-3p is significantly correlated with distant metastasis and clinical stage (Huang et al., 2019).
Furthermore, some studies have also reported that miR-129-2-3p is associated with other human diseases. A previous study reported that miR-129-2-3p directly regulates the translation of two genes involved in inflammatory responses and apoptosis (Ccr2 and Casp6), and overexpression of miR-129-2-3p can promote wound healing in type 2 diabetic mice (Umehara et al., 2019). MiR-129-2-3p levels are significantly reduced in patients with ischemic stroke (IS) and are negatively associated with the risk of IS (Chen et al., 2020). The expression of miR-129-2-3p is up-regulated in cortical brain tissue and plasma of refractory temporal lobe epilepsy patients (Sun et al., 2016).
In the past few decades, some methods have been used to detect miRNA, including quantitative real-time polymerase chain reaction (qRT-PCR) (Chen et al., 2005), microarray (Thomson et al., 2004), northern blotting (Válóczi et al., 2004) and modified invader assay (Allawi et al., 2004). Some new detection methods have recently been invented, such as representative loop-mediated isothermal amplification (LAMP) (Li et al., 2011) and rolling circle amplification (RCA) (Xu et al., 2018). In this study, an RCA-based biosensor system was used to perform the amplification detection of miRNA (miR-129-2-3p) in vitro. This method achieves signal amplification and biosensing, which has exciting potential in clinical diagnosis.
Materials & Methods
Materials
The DEPC Treated Water (DEPC-H2O) and deoxyribonucleotides mixture (dNTPs) were purchased from Sangon Biotech (Shanghai, China). Phi29 DNA polymerase (10,000 U/mL) and 10 ×phi29 DNA polymerase reaction buffer, SYBR Green I were obtained from Thermo Fisher Scientific (Shanghai, China). T4 DNA ligase and 10 × T4 DNA ligase reaction buffer were provided by TaKaRa Biotechnology Co., Ltd. (Dalian, China). The padlock probe and oligonucleotides in this study were synthesized and PAGE purified by Sangon Biotech (Shanghai, China), the padlock probe was modified with the 5′-phosphate group. The sequences (5′–3′) were shown in Table 1.
Table 1. Sequences used in this study.
| Serial number | Name | Sequence |
|---|---|---|
| 1 | miR-129-2-3p | AAGCCCUUACC CCAAAAAGCAU |
| 2 | 3p-A | CAGCCCUUACC CCAAAAAGCAU |
| 3 | 3p-B | AAGCCCUUUCC CCAAAAAGCAU |
| 4 | 3p-C | AAGCCCUUACG GCAAAAAGCAU |
| 5 | 3p-D | AAGCCCUUACC UCAAAAAGCAU |
| 6 | 3p-E | AAGCCCUUACC CCAAAAAGCAA |
| 7 | Padlock probe 1(PP1) | GGTAAGGGCTTAAATCAACCGTACGGCTCAAACGCATGCTTTTTGG |
| 8 | Random padlock probe 1(RP1) | GGTAAGGGCTTAAACCTCAAGTCTACCAAGGACGCATGCTTTTTGG |
| 9 | Random padlock probe 2(RP2) | GGTAAGGGCTTAAATCAACGAGCGTCCTCAAACGCATGCTTTTTGGTATACAAC |
| 10 | Padlock probe 2 (PP2) | GGTAAGGGCTTCCGTACGGACAACCTACTACCTCACCGTACGGCTATA CCTACTACCTA CCGTACGGATGCTTTTTGG |
Ligation reaction of padlock probe and miRNA
The ligation was carried out in 10 µL of the reaction system. 1 µL of 10 × T4 DNA ligase buffer, 2 µL of 10 µM padlock probe, 2 µL of miRNA, and 4 µL of H2O were added to a PCR tube and heated at 90 °C for 3 min for annealing reaction, and then slowly cooled down to room temperature (RT). Subsequently, 350 U/mL T4 DNA ligase (1µL) was added to the reaction solution and incubated at RT for 3 h.
The RCA reaction of miRNA
After the ligation reaction, 2 µL of 10 mM dNTP (1 mM), 2 µL of 10 × phi29 DNA buffer, 5.7 µL of H2O, and 0.3 µL of phi29 DNA polymerase (3U) were added to the tube and then kept at 30 °C for 3 h to induce the RCA reaction. Finally, the enzymatic reaction was stopped by maintaining the temperature at 65 °C for 10 min. RCA reaction was carried out in T1 Thermocycler (Biometra, Jena, Germany).
Fluorescence detection
To detect the fluorescence of hybridization events of target/linear padlock probes, 6 µL RCA product and 2 µL of 100 × SYBR Green I were mixed, then incubated at RT for 30 min and diluted to a final volume of 200 µL with DEPC-H2O. The fluorescent spectra were detected by the Hitachi F-7000 fluorescence spectrometer (Hitachi, Ltd., Tokyo, Japan) at RT. The excitation wavelength was set to 480 nm with an emission range of 500 nm–700 nm. A fluorescence peak emission wavelength of 550 nm was recorded to evaluate the capability of our system.
Gel electrophoresis analysis
The nucleic acids produced by the RCA reaction were analyzed by PAGE (polyacrylamide gel electrophoresis). Firstly, the dye was pre-mixed with 100 µL DiGelRed, 50 µL loading dye, and 2 µL cyber gold, then a 20 µL aliquot of RCA product solution was mixed with 20 µL mixed dye solution. Subsequently, 5 µL of the resulting solution load was placed into the lane for 30% PAGE. Gel electrophoresis was performed for 30 min at 195 V in a 5 × TBE solution. The ChemiDoc XRS imaging system (BIO-RAD, USA) was used to visualize the gel images.
Extraction of microarray gene expression data from breast cancer patient datasets
The serum microarray datasets of breast cancer patients were extracted from Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). GSE73002 included 1670 breast cancer patients and 2,682 healthy volunteers. Receiver operating characteristics (ROC) curve analysis was performed to analyze the ability of miR-129-2-3p as a serum biomarker for breast cancer. ROC curve was generated with SPSS software.
Patients and specimens
The research consisted of 6 breast cancer samples and six healthy volunteer samples. All the patients under went breast resection at the First Affiliated Hospital of Fujian Medical University between January 2020 and June 2021. The inclusion criteria for patients were: (1) histologically confirmed breast cancer; (2) no history of other malignancy; (3) no prior neoadjuvant chemotherapy. The study was performed with the approval of the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from the patients, and specimens were stored in the hospital database and used for research.
Results
Extraction of microarray gene expression data from breast cancer patient datasets
In order to explore the expression of miR-129-2-3p in breast cancer, GSE73002 datasets were analyzed, revealing that the level of miR-129-2-3p was significantly higher in breast cancer than in healthy volunteers (shown in Fig. 1A). ROC curve analysis showed that miR-129-2-3p expression has potential diagnostic value for breast cancer. Data from the GSE73002 dataset showed that miR-129-2-3p may be an important diagnostic factor for breast cancer (Area Under Curve (AUC) = 0.928; 95% Cl [0.918–0.938]; p < 0.001; Fig. 1B).
Figure 1. Extraction of microarray gene expression data from breast cancer patient datasets.
(A) The analysis of GSE73002 data sets showed that in breast cancer, the level of miR-129-2-3p was significantly higher than the healthy volunteers. (B) ROC curve analysis showed that expression of miR-129-2-3p has potential diagnostic value for breast cancer.
The feasibility of RCA-based biosensor system strategy
The feasibility of the RCA-based biosensor system was verified with fluorescence spectral characteristics. Figure 2A showed the fluorescence emission spectra in the absence (curve b) and presence (curve a) of miR-129-2-3p. Low fluorescence intensity was observed in solutions without miR-129-2-3p. On the contrary, the fluorescence intensity was significantly enhanced after miR-129-2-3p was introduced into the solutions (curve a). These results indicated that miR-129-2-3p could induce ligation reactions, followed by RCA reactions, subsequently leading to the production of a large number of dsDNA fragments. To further explore the feasibility of our strategy, PAGE gel electrophoresis was performed, as shown in Fig. 2B. No bands were observed in the absence of miR-129-2-3p (lane a), but a distinct band appeared in the presence of miR-129-2-3p (lane b). Therefore, the results of fluorescence spectral characteristics and PAGE gel electrophoresis suggested that the RCA-based biosensor system can be used to detect miR-129-2-3p.
Figure 2. The feasibility of RCA-based biosensor system.
(A) Fluorescence spectra of RCA-based biosensor system in the absence (b) and presence (a) of target miR-129-2-3p; (B) PAGE gel electrophoresis results for the amplification products of absence (a) and presence (b) of target miR-129-2-3p.
Optimization of experimental conditions
The incubation time for ligation and amplification and the concentration of phi29 DNA polymerase and dNTPs play a significant role in these experiments. Therefore, the experimental conditions were optimized to achieve the best performance. As illustrated in Fig. 3A, with the increase of ligation time, the fluorescence changes gradually increased and to stabilized within 3 h. Therefore, a 3 h ligation time was chosen for further experiments. Similarly, the number of RCA reaction products is closely related to the polymerization time, and the measured values are shown in Fig. 3B. Thus, the RCA reactions lasts for 3 h in the proposed biosensor system. Subsequently, the effects of the amount of phi29 DNA polymerase and the concentration of dNTPs on signal intensity were evaluated to further evaluate the biosensor system. All measured data are shown in Figs. 3C and 3D, respectively. Consequently, 2 mM dNTP and 3 U of phi29 DNA polymerase were used in subsequent experiments.
Figure 3. The relationship between fluorescence intensity and ligation time (A), polymerization time (B), and the concentration of phi29 DNA polymerase (C) and dNTPs (D).
F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
Sensitivity of RCA-based biosensor system for miRNA detection
In order to test the capability of the RCA-based biosensor system for miRNA detection, different concentrations of miR-129-2-3p solution were detected. As shown in Fig. 4A, the fluorescence intensity increased with the increase of miR-129-2-3p concentration within 0–150 µM. It indicated that the change in fluorescence intensity reflected the concentration of miR-129-2-3p. As illustrated in Fig. 4B, there was a significant linear relationship between the fluorescence signal and target concentration in the range of 20 nM to 150 µM, and the correlation coefficient R2 was 0.9933. The detection limit (LOD) of the aptasensor was estimated to be 50 nM (S/N = 3). This is the first time that an RCA-based biosensor system has been used to detect miR-129-2-3p, which is expected to provide a sensitive detection method for miR-129-2-3p as a target marker in clinical practice.
Figure 4. (A) Fluorescence intensity of miR-129-2-3p miRNA at different concentrations; (B) linear relationship between fluorescence intensity ratio (F-F0) and target miR-129-2-3p miRNA concentration, from 50 nM to 200 µM.
F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
In the RCA-based biosensor system, the fluorescence signal is caused by SYBR Green I interacting with the dsDNA fragments, which determines the fluorescence signal intensity. Therefore, the padlock probe 2 was designed containing three palindromes to indicate the relationship between the fluorescence signal and the palindromic fragment number. Moreover, two random padlock probes without palindromes were designed to indicate the relationship between the fluorescence signal and the palindromic fragment number. As shown in Fig. 5A, the fluorescence intensity increased about 2 times when the number of palindrome fragments increased to three. As illustrated in Fig. 5B, the fluorescence signal of the two random padlock probes was lower than that of padlock probe1. It seemed that the performance of the RCA-based biosensor system for miR-129-2-3p detection could be further improved by optimizing the number of palindrome fragments.
Figure 5. (A) Comparison of padlock probe 1(PP1) to miR-129-2-3p with padlock probe 2(PP2), where F and F0 are the fluorescence intensity corresponding to miR-129-2-3p and blank, respectively. (B) Comparison of padlock probe 1(PP1) to miR-129-2-3p with random padlock probe 1 and 2.
The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb0 are the fluorescence intensity in the presence and absence of random padlock probe1 and 2(PP1 and PP2), respectively, while Fa and Fa0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, the relative signal of miR-129-2-3p is established as 100 (%). The error bar was calculated from two independent experiments.
Detection specificity of miR-129-2-3p
Apart from the sensitivity of detection, specificity is another key factor for the application of this strategy for miR-129-2-3p analysis. The specificity of detection for miRNA is of great significance due to the short length and similar base sequence of miRNAs. So, five mutations of miR-129-2-3p (3p-A, 3p-B, 3p-C, 3p-D and 3p-E) and miR-129-2-3p were used to assess the detection specificity of the RCA-based biosensor system. As shown in Fig. 6, only target miR-129-2-3p elicited a high fluorescence signal. In contrast, the other five mutated miRNAs only induced slight signal changes: 33.1%, 19.4%, 1.5%, 10.6%, and 21.7%, respectively, compared with perfectly matched miR-129-2-3p. Therefore, the padlock probe1 in this work could specifically hybridize with miR-129-2-3p and promote subsequent reactions. The RCA-based biosensor system can be used to distinguish miR-129-2-3p from other non-target miRNAs.
Figure 6. Detection specificity of the RCA-based biosensor system toward miR-129-2-3p over other mutated miRNAs.
The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb0 are the fluorescence intensity in the presence and absence of mutated miRNAs, respectively, while Fa and Fa0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, relative signal of miR-129-2-3p is established as 100 (%). The error bar was calculated from two independent experiments.
Detection of real samples
To study the feasibility of this method in real sample analysis, the fluorescence intensity of miR-129-2-3p was detected in the serum of breast cancer patients and healthy people. As shown in Fig. 7, the fluorescence intensity of miR-129-2-3p in breast cancer patients is about twice that of healthy people.
Figure 7. Detection of the fluorescence intensity of miR-129-2-3p in the serum of breast cancer patients and healthy people.
F and F0 were the fluorescence intensity induced by sample and Blank, respectively.
Discussion
MiR-129-2-3p is a member of the miR-129 family, and its abnormal expression is frequently detected in tumors; MiR129-2-3p is thought to have an inhibitory effect on various types of tumors. Over the past decades, different methods were used to detect miRNAs, including quantitative real-time polymerase chain reaction (qRT-PCR) (Chen et al., 2005), microarray (Thomson et al., 2004), northern blotting (Válóczi et al., 2004) and modified invader assay (Allawi et al., 2004). However, these methods still have some limitations in clinical diagnosis. For example, PCR may affect gene expression. Northern blotting is a time-consuming process with low sensitivity. Microarray cannot be used due to high cost, lower sensitivity, and poor reproducibility. Herein, a versatile fluorescent bioanalysis platform for sensitive and specific screening of target miRNA (miR-129-2-3p miRNA) was innovatively designed by using target-induced rolling circle amplification (RCA) for efficient signal amplification.
The principle of the RCA-based biosensor system for detecting target miRNA is described in Scheme S1. This system consists of padlock probe 1 (including a palindrome sequence) complementary to the sequence of the target miRNA, target miRNA, ligase and polymerase, and SYBR Green I. In the presence of target miRNA, cyclized padlock probe 1 is obtained with the help of T4 DNA ligase. The RCA polymerization reaction is initiated in the presence of phi29 DNA polymerase and dNTPs. As a result, the RCA reaction produced a long single stranded DNA, many copies of dsDNA fragments of the target because of the self-hybridization of the palindromic sequences. Subsequently, the dsDNA binds to SYBR Green I, and the fluorescence signal can be detected by the fluorescence spectrometer. Through this method, as long as target miRNA and padlock probe1 are connected during the reaction, a large number of dsDNA fragments can be produced after RCA. Since the RCA products are long dsDNA, SYBR Green I is an asymmetrical cyanine dye used as a nucleic acid stain to enhance the fluorescence intensity. Therefore, the RCA-based biosensor system is likely to provide good sensitivity for miR-129-2-3p detection. As a result, miR-129-2-3p miRNA concentrations as low as 50 nM can be detected. In the analysis of real samples, the fluorescence intensity of miR-129-2-3p in breast cancer patients is about twice that in healthy people. Therefore, the results indicated that the RCA -based biosensor system has the potential to become a valuable platform for miRNA detection in clinical diagnosis and biomedical study.
Conclusions
In summary, we have developed a specific fluorescent detection method for miR-129-2-3p using a palindromic padlock probe in an RCA-based biosensor system. Target miRNA is used as a polymeric primer to hybridize with the padlock probe. The RCA reactions can easily occur in the presence of polymerases, which produces a large number of dsDNA fragments. SYBR Green I intercalates the dsDNA fragments, and the fluorescence signal is detected. Utilizing this RCA-based biosensor system, miR-129-2-3p can be detected at a concentration as low as 50 nM with a good linear response range, even using only one palindromic padlock probe. In the analysis of real samples, the expression of miR-129-2-3p in breast cancer patients was about twice that of healthy people. This research highlights the potential of this sensing system to detect miR-129-2-3p as a tumor biomarker in cancer diagnosis and prognosis. It also offers a new amplification technique for the biological studies of miR-129-2-3p.
Supplemental Information
Hybridization of target to padlock probe by annealing. Circular padlock probe is formed via ligation in the presences of T4 DNA ligase. RCA reaction occurs and target miRNA is amplified to produce a large amount of dsDNA. As a result, dsDNA are able to bind SYBR Green I, then fluorescence signal can be read.
The feasibility of RCA-based biosensor system. (A) Fluorescence spectra of RCA-based biosensor system in the absence (b) and presence (a) of target miR-129-2-3p; (B) PAGE gel electrophoresis results for the amplification products of absence (a) and presence (b) of target miR-129-2-3p.
The relationship between fluorescence intensity and ligation time (A), polymerization time (B), and the concentration of phi29 DNA polymerase (C) and dNTPs (D). F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
(A) Fluorescence intensity of miR-129-2-3p miRNA at different concentrations; (B) Linear relationship between fluorescence intensity ratio (F-F0) and target miR-129-2-3p miRNA concentration, from 50 nM to 200 μM. F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
(A) Comparison of padlock probe 1 to miR-129-2-3p miRNA with padlock probe 2, where F and F0 are the fluorescence intensity corresponding to miR-129-2-3p and blank, respectively. (B) Comparison of padlock probe 1 to miR-129-2-3p miRNA with random padlock probe1 and 2, The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb 0 are the fluorescence intensity in the presence and absence of random padlock probe1 and 2, respectively, while Fa and Fa0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, relative signal of miR-129-2-3p miRNA is established as 100 (%). The error bar was calculated from two independent experiments.
Detection specificity of the RCA-based biosensor system toward miR-129-2-3p over other mutated miRNAs. The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb0 are the fluorescence intensity in the presence and absence of mutated miRNAs, respectively, while Fa and Fa 0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, relative signal of miR-129-2-3p miRNA is established as 100 (%). The error bar was calculated from two independent experiments.
Funding Statement
The authors received no funding for this work.
Contributor Information
Dianping Tang, Email: dianping.tang@fzu.edu.cn.
Qingqiang Lin, Email: qingqianglin@fjnu.edu.cn.
Additional Information and Declarations
Competing Interests
The authors declare there are no competing interests.
Author Contributions
Yan Ye conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
Yao Lin conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
Zilin Chi conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
Jiasheng Zhang conceived and designed the experiments, performed the experiments, prepared figures and/or tables, and approved the final draft.
Fan Cai conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
Youzhi Zhu analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
Dianping Tang conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
Qingqiang Lin conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University.
Data Availability
The following information was supplied regarding data availability:
The raw data is available in the Supplementary Files.
References
- Allawi et al. (2004).Allawi H, Dahlberg J, Olson S, Lund E, Olson M, Ma W, Takova T, Neri B, Lyamichev V. Quantitation of microRNAs using a modified Invader assay. RNA. 2004;10(7):1153–1161. doi: 10.1261/rna.5250604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ambros (2001).Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–826. doi: 10.1016/s0092-8674(01)00616-x. [DOI] [PubMed] [Google Scholar]
- Asaga et al. (2011).Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano A, Hoon D. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical Chemistry. 2011;57(1):84–91. doi: 10.1373/clinchem.2010.151845. [DOI] [PubMed] [Google Scholar]
- Bartel (2004).Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi: 10.1016/S0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
- Brito et al. (2014).Brito J, Gomes C, Guimarães A, Campos K, Gomez R. Relationship between micro RNA expression levels and histopathological features of dysplasia in oral leukoplakia. Journal of Oral Pathology & Medicine. 2014;43(3):211–216. doi: 10.1111/jop.12112. [DOI] [PubMed] [Google Scholar]
- Cao et al. (2011).Cao Y, De Pinho R, Ernst M, Vousden K. Cancer research: past, present and future. Nature Reviews Cancer. 2011;11(10):49–754. doi: 10.1038/nrc3138. [DOI] [PubMed] [Google Scholar]
- Chen et al. (2020).Chen C, Jiang J, Fang M, Zhou L, Chen Y, Zhou J, Song Y, Kong G, Zhang B, Jiang B, Li H, Peng C, Liu S. MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma. Journal of Cancer. 2020;11(11):3216. doi: 10.7150/jca.41492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen et al. (2005).Chen C, Ridzon D, Broomer A, Zhou Z, Lee D, Nguyen J, Barbisin M, Xu N, Mahuvakar V, Andersen M, Lao K, Livak K, Guegler K. Real-time quantification of microRNAs by stem–loop RT–PCR. Nucleic Acids Research. 2005;33(20):e179-e179. doi: 10.1093/nar/gni178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gao et al. (2016).Gao Y, Feng B, Han S, Lu L, Chen Y, Chu X, Wang R, Chen L. MicroRNA-129 in human cancers: from tumorigenesis to clinical treatment. Cellular Physiology and Biochemistry. 2016;39(6):2186–2202. doi: 10.1159/000447913. [DOI] [PubMed] [Google Scholar]
- Gregory et al. (2004).Gregory R, Yan K, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhatta R. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235–240. doi: 10.1038/nature03120. [DOI] [PubMed] [Google Scholar]
- Huang et al. (2019).Huang S, Lv Z, Wen Y, Wei Y, Zhou L, Ke Y, Zhang Y, Xu Q, Li L, Guo Y, Li D, Xie C, Guo Y, Cheng J. miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population. Journal of Cellular and Molecular Medicine. 2019;23(1):167–176. doi: 10.1111/jcmm.13901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jiang et al. (2005).Jiang J, Lee E, Gusev Y, Schmittgen T. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Research. 2005;33(17):5394–5403. doi: 10.1093/nar/gki863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kang et al. (2013).Kang M, Li Y, Liu W, Wang R, Tang A, Hao H, Liu Z, Ou H. miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. International Journal of Molecular Medicine. 2013;32(1):51–58. doi: 10.3892/ijmm.2013.1384. [DOI] [PubMed] [Google Scholar]
- Krazinski et al. (2019).Krazinski B, Kiewisz J, Jewsiewicka A, Kowalczyk A, Grzegrzolka J, Godlewski J, Kwiatkowski P, Dziegiel P, Kmiec Z. Altered expression of DDR1 in clear cell renal cell carcinoma correlates with miR-199a/b-5p and patients’ outcome. Cancer Genomics & Proteomics. 2019;16(3):179–193. doi: 10.21873/cgp.20124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li et al. (2011).Li C, Li Z, Jia H, Yan J. One-step ultrasensitive detection of microRNAs with loop-mediated isothermal amplification (LAMP) Chemical Communications. 2011;47(9):2595–2597. doi: 10.1039/c0cc03957h. [DOI] [PubMed] [Google Scholar]
- Li et al. (2014).Li J, Tan S, Kooger R, Zhang C, Zhang Y. MicroRNAs as novel biological targets for detection and regulation. Chemical Society Reviews. 2014;43(2):506–517. doi: 10.1039/C3CS60312A. [DOI] [PubMed] [Google Scholar]
- Lu et al. (2013).Lu C, Lin K, Tien M, Wu C, Uen Y, Tsen T. Frequent DNA methylation of miR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes, Chromosomes and Cancer. 2013;52(7):636–643. doi: 10.1002/gcc.22059. [DOI] [PubMed] [Google Scholar]
- Luan et al. (2016).Luan Q, Zhang B, Li X, Guo M. MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. European Review for Medical and Pharmacological Sciences. 2016;20(20):4257–65. [PubMed] [Google Scholar]
- Luby & Zheng (2017).Luby BM, Zheng G. Specific and direct amplified detection of MicroRNA with microRNA: argonaute-2 cleavage (miRACle) beacons. Angewandte Chemie International Edition. 2017;56(44):13704–13708. doi: 10.1002/ange.201707366. [DOI] [PubMed] [Google Scholar]
- Ma et al. (2019).Ma L, Chen X, Li C, Cheng R, Gao Z, Meng X, Sun C, Liang C, Liu Y. miR-129-5p and-3p co-target WWP1 to suppress gastric cancer proliferation and migration. Journal of Cellular Biochemistry. 2019;120(5):7527–7538. doi: 10.1002/jcb.28027. [DOI] [PubMed] [Google Scholar]
- Rossi (2009).Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell. 2009;137(6):990–992. doi: 10.1016/j.cell.2009.05.038. [DOI] [PubMed] [Google Scholar]
- Sawyers (2008).Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548–552. doi: 10.1038/nature06913. [DOI] [PubMed] [Google Scholar]
- Schetter et al. (2008).Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N, Yuen S, Chan T, Kwong D, Au G, Liu C, Calin G, Croce C, Harris C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299(4):425–436. doi: 10.1001/jama.299.4.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shazadi et al. (2014).Shazadi K, Petrovski S, Roten A, Miller H, Huggins R, Brodie M, Pirmohamed M, Johnsong M, Marsona Anthony., Brien T, Sills G. Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Research. 2014;108(10):1797–1805. doi: 10.1016/j.eplepsyres.2014.08.022. [DOI] [PubMed] [Google Scholar]
- Sun et al. (2016).Sun Y, Wang X, Wang Z, Zhang Y, Che N, Luo X, Tan Z, Sun X, Li X, Yang K, Wang G, Luan L, Liu Y, Zheng X, Wei M, Cheng H, Yin J. Expression of microRNA-129-2-3p and microRNA-935 in plasma and brain tissue of human refractory epilepsy. Epilepsy Research. 2016;127:276–283. doi: 10.1016/j.eplepsyres.2016.09.016. [DOI] [PubMed] [Google Scholar]
- Tang et al. (2016).Tang X, Tang J, Liu X, Zeng L, Cheng C, Luo Y, Li L, Qin S, Sang Y, Deng L, Lv X. Downregulation of miR-129-2 by promoter hypermethylation regulates breast cancer cell proliferation and apoptosis. Oncology Reports. 2016;35(5):2963–2969. doi: 10.3892/or.2016.4647. [DOI] [PubMed] [Google Scholar]
- Tanoglu et al. (2021).Tanoglu E, Arıkan Y, Kabukcuoglu Y, Kabukcuoglu F, Tanoglu A, Ozturk S. Mir-129-2-3p has tumor suppressor role in ewing sarcoma cell lines and cancer tissue samples. Brazilian Archives of Biology and Technology. 2021;64:e21210306. doi: 10.1590/1678-4324-2021210306. [DOI] [Google Scholar]
- Thomson et al. (2004).Thomson M, Parker J, Perou C, Hammond S. A custom microarray platform was analysis of miRNA gene expression. Nature Methods. 2004;1:47–53. doi: 10.1038/nmeth704. [DOI] [PubMed] [Google Scholar]
- Tian et al. (2015).Tian X, Zhang L, Sun L, Li M. Epigenetic regulation of miR-129-2 leads to overexpression of PDGFRa and FoxP1 in glioma cells. Asian Pacific Journal of Cancer Prevention. 2015;16(14):6129–6133. doi: 10.7314/APJCP.2015.16.14.6129. [DOI] [PubMed] [Google Scholar]
- Umehara et al. (2019).Umehara T, Mori R, Mace K, Murase T, Abe Y, Yamamoto T, Ikematsu K. Identification of specific miRNAs in neutrophils of type 2 diabetic mice: overexpression of miRNA-129-2-3p accelerates diabetic wound healing. Diabetes. 2019;68(3):617–630. doi: 10.2337/db18-0313. [DOI] [PubMed] [Google Scholar]
- Válóczi et al. (2004).Válóczi A, Hornyik C, Varga N, Burgyán J, Kauppinen S, Havelda Z. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Research. 2004;32(22):e175-e175. doi: 10.1093/nar/gnh171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Volinia et al. (2006).Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt R, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris C, Croce C. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(7):2257–2261. doi: 10.1073/pnas.0510565103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang et al. (2021).Wang G, Luan Z, Che N, Yan D, Sun X, Zhang C, Yin J. Inhibition of microRNA-129-2-3p protects against refractory temporal lobe epilepsy by regulating GABRA1. Brain and Behavior. 2021;11:e02195. doi: 10.1002/brb3.2195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xiao et al. (2015).Xiao Y, Li X, Wang H, Wen R, He J, Tang J. Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. Journal of Cellular and Molecular Medicine. 2015;19(9):2172–2180. doi: 10.1111/jcmm.12597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xu et al. (2018).Xu H, Wu D, Zhang Y, Shi H, Ouyang C, Li F, Jia L, Yu S, Wu Z. RCA-enhanced multifunctional molecule beacon-based strand-displacement amplification for sensitive microRNA detection. Sensors and Actuators B: Chemical. 2018;258:470–477. doi: 10.1016/j.snb.2017.09.050. [DOI] [Google Scholar]
- Xu et al. (2019).Xu H, Zhang S, Ouyang C, Wang Z, Wu D, Liu Y, Jiang Y, Wu Z. DNA nanostructures from palindromic rolling circle amplification for the fluorescent detection of cancer-related microRNAs. Talanta. 2019;192:175–181. doi: 10.1016/j.talanta.2018.07.090. [DOI] [PubMed] [Google Scholar]
- Yang et al. (2015).Yang Y, Huang J, Zhang X, Shen L. MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Molecular and Cellular Biochemistry. 2015;404(1):229–239. doi: 10.1007/s11010-015-2382-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yu et al. (2013a).Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, Le Y, Gu J. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Medical Oncology. 2013a;30(1):1–6. doi: 10.1007/s12032-012-0365-y. [DOI] [PubMed] [Google Scholar]
- Yu et al. (2013b).Yu X, Song H, Xia T, Han S, Xiao B, Luo L, Xi Y, Guo J. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013b;532(1):87–93. doi: 10.1016/j.gene.2013.09.048. [DOI] [PubMed] [Google Scholar]
- Zhang et al. (2021).Zhang Y, Liu H, Zhang Q, Zhang Z. Long noncoding RNA LINC01006 facilitates cell proliferation, migration, and epithelial-mesenchymal transition in lung adenocarcinoma via targeting the MicroRNA 129-2-3p/CTNNB1 axis and activating Wnt/ β-catenin signaling pathway. Molecular and Cellular Biology. 2021;41(6):e00380-20. doi: 10.1128/MCB.00380-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Hybridization of target to padlock probe by annealing. Circular padlock probe is formed via ligation in the presences of T4 DNA ligase. RCA reaction occurs and target miRNA is amplified to produce a large amount of dsDNA. As a result, dsDNA are able to bind SYBR Green I, then fluorescence signal can be read.
The feasibility of RCA-based biosensor system. (A) Fluorescence spectra of RCA-based biosensor system in the absence (b) and presence (a) of target miR-129-2-3p; (B) PAGE gel electrophoresis results for the amplification products of absence (a) and presence (b) of target miR-129-2-3p.
The relationship between fluorescence intensity and ligation time (A), polymerization time (B), and the concentration of phi29 DNA polymerase (C) and dNTPs (D). F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
(A) Fluorescence intensity of miR-129-2-3p miRNA at different concentrations; (B) Linear relationship between fluorescence intensity ratio (F-F0) and target miR-129-2-3p miRNA concentration, from 50 nM to 200 μM. F and F0 were the fluorescence intensity induced by target miRNA and Blank, respectively. The error bar was calculated from two independent experiments.
(A) Comparison of padlock probe 1 to miR-129-2-3p miRNA with padlock probe 2, where F and F0 are the fluorescence intensity corresponding to miR-129-2-3p and blank, respectively. (B) Comparison of padlock probe 1 to miR-129-2-3p miRNA with random padlock probe1 and 2, The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb 0 are the fluorescence intensity in the presence and absence of random padlock probe1 and 2, respectively, while Fa and Fa0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, relative signal of miR-129-2-3p miRNA is established as 100 (%). The error bar was calculated from two independent experiments.
Detection specificity of the RCA-based biosensor system toward miR-129-2-3p over other mutated miRNAs. The relative signal is estimated from (Fb-Fb0)/(Fa-Fa0) × 100. Fb and Fb0 are the fluorescence intensity in the presence and absence of mutated miRNAs, respectively, while Fa and Fa 0 are the fluorescence intensity in the presence and absence of miR-129-2-3p, respectively. In this section, relative signal of miR-129-2-3p miRNA is established as 100 (%). The error bar was calculated from two independent experiments.
Data Availability Statement
The following information was supplied regarding data availability:
The raw data is available in the Supplementary Files.